Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Phathom Pharmaceuticals Inc shares valued at $127,760 were sold by Nabulsi Azmi on Jul 15 ’24. At $11.72 per share, Nabulsi Azmi sold 10,901 shares. The insider’s holdings dropped to 240,421 shares worth approximately $3.12 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Henderson Molly sold 4,325 shares, netting a total of over 50,689 in proceeds. Following the sale of shares at $11.72 each, the insider now holds 99,447 shares.
Before that, Curran Terrie had sold 33,848 shares from its account. In a trade valued at $396,699, the President and Chief Executive traded Phathom Pharmaceuticals Inc shares for $11.72 each. Upon closing the transaction, the insider’s holdings decreased to 33,848 shares, worth approximately $4.9 million.
As published in their initiating research note from Stifel on May 03, 2024, Phathom Pharmaceuticals Inc [PHAT] has been a Buy and the price target has been revised to $24. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in early January. As of August 09, 2023, H.C. Wainwright has initiated its “Buy” rating for PHAT. Earlier on May 11, 2023, Evercore ISI upgraded its rating. Their new recommendation was “an Outperform” for PHAT stock which previously was a “an In-line”.
Analyzing PHAT Stock Performance
During the last five days, there has been a surge of approximately 4.34%. Over the course of the year, Phathom Pharmaceuticals Inc shares have jumped approximately 42.17%. Shares of the company reached a 52-week high of $13.63 on 08/19/24 and a 52-week low of $6.07 on 02/13/24. A 50-day SMA is recorded $11.42, while a 200-day SMA reached $9.54. Nevertheless, trading volume fell to 0.74 million shares from 0.51 million shares the previous day.
Support And Resistance Levels for Phathom Pharmaceuticals Inc (PHAT)
According to the 24-hour chart, there is a support level at 12.53, which, if violated, would cause prices to drop to 12.07. In the upper region, resistance lies at 13.40. The next price resistance is at 13.81. RSI (Relative Strength Index) is 61.94 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.83, which suggests the price will decrease in the coming days. Percent R is at 20.50%, indicating bullish price movement. Stochastics%K at holding indicates that the stock is to be held.
